Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of
RNS Number : 6206Q MaxCyte, Inc. 28 October 2021 MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs Nkarta to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform to accelerate the development of its oncology
RNS Number : 2022Q MaxCyte, Inc. 26 October 2021 MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021 GAITHERSBURG, MD , October 26, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 1277O MaxCyte, Inc. 06 October 2021 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name MAXCYTE, INC. UK or Non- UK Issuer Non- UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or
RNS Number : 8000N MaxCyte, Inc. 01 October 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Annual General Meeting Change of Director Gaithersburg, Maryland - 1 October 2021 : MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company
RNS Number : 7698N MaxCyte, Inc. 01 October 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 October 2021 : MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company focused on providing enabling
RNS Number : 1652M MaxCyte, Inc. 17 September 2021 MaxCyte Set to Join Russell 2000® Index GAITHERSBURG, MD , September 16, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 6380L MaxCyte, Inc. 14 September 2021 MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections GAITHERSBURG, MD , September 13, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell
